US pharmaceuticals vs Australia’s PBS
Australia’s Pharmaceutical Benefits Scheme (PBS) remains a global leader in medicine price control despite intense lobbying and trade pressure from US pharmaceutical corporations, which seek to weaken its cost-effectiveness mechanisms. The PBS, valued at A$18 billion annually, faces ongoing threats from industry groups like PhRMA, which have pushed for retaliatory tariffs and stronger patent protections through trade agreements like AUSFTA.
Australia’s Pharmaceutical Benefits Scheme (PBS) stands as one of the world’s most effective medicine price-control systems, protecting patients from exploitative pricing by multinational pharmaceutical corporations. The PBS, with an annual expenditure of A$18 billion, operates as a collective purchaser, negotiating drug prices based on cost-effectiveness assessments by the independent Pharmaceutical Benefits Advisory Committee (PBAC). This system limits the ability of corporations like Eli Lilly (valued at US$900 billion), Johnson & Johnson (US$450 billion), and AbbVie (US$400 billion) to extract monopoly profits, making it a recurring target for industry lobbying. US pharmaceutical corporations, collectively worth US$10 trillion, exert significant influence through trade negotiations, intellectual property rules, and market power. The Pharmaceutical Research and Manufacturers of America (PhRMA) has repeatedly criticized the PBS, arguing it undervalues innovative medicines by forcing lower prices than those in less regulated markets. In 2025, PhRMA urged the Trump administration to classify the PBS as an unfair trade practice and consider retaliatory tariffs against Australia. The Australia-United States Free Trade Agreement (AUSFTA), negotiated in 2005, has been criticized for granting US pharmaceutical interests greater influence over Australian medicine policy. While the agreement strengthened intellectual property protections, Australia retains control over medicine listings, subsidy levels, and cost-effectiveness assessments. Critics argue AUSFTA’s provisions could pressure Australia to weaken its pricing system, though successive governments have rejected calls to dismantle the PBS. Pharmaceutical companies can refuse to supply medicines through the PBS if negotiated prices are deemed too low, leveraging their market power to pressure governments into higher payments. The industry’s push for stronger patent protections and longer market exclusivity delays generic competition, helping maintain higher prices. Despite these challenges, the PBS remains a critical counterbalance to the market dominance of multinational drug corporations, ensuring affordable access to essential medicines for Australians.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.